Variations in S100A8/A12 Gene Expression Are Associated with the Efficacy of Nintedanib and Acute Exacerbation Development in Idiopathic Pulmonary Fibrosis Patients.

[1]  Kakuhiro Yamaguchi,et al.  Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation. , 2022, Respiratory investigation.

[2]  M. Kusumoto,et al.  Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial , 2022, European Respiratory Journal.

[3]  Hong Chen,et al.  S100A12 as Biomarker of Disease Severity and Prognosis in Patients With Idiopathic Pulmonary Fibrosis , 2022, Frontiers in Immunology.

[4]  N. Inui,et al.  Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis. , 2021, Respiratory investigation.

[5]  Hiromasa Yamamoto,et al.  The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis , 2020, Journal of Molecular Medicine.

[6]  K. Tatsumi,et al.  S100A12 inhibits fibroblast migration via the receptor for advanced glycation end products and p38 MAPK signaling , 2019, In Vitro Cellular & Developmental Biology - Animal.

[7]  L. Vernhet,et al.  Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib. , 2019, International immunopharmacology.

[8]  Jian Ma,et al.  S100A8/A9 in Inflammation , 2018, Front. Immunol..

[9]  A. Zarbock,et al.  Alarmin S100A8 Activates Alveolar Epithelial Cells in the Context of Acute Lung Injury in a TLR4-Dependent Manner , 2017, Front. Immunol..

[10]  B. Ryffel,et al.  Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[11]  D. Foell,et al.  S100 proteins expressed in phagocytes: a novel group of damage‐associated molecular pattern molecules , 2007, Journal of leukocyte biology.